Carbogen and nicotinamide with radiation feasible for bladder cancer

Carbogen and nicotinamide with radiation feasible for bladder cancer

(HealthDay)—The use of concurrent carbogen and nicotinamide (CON) with radiation therapy is feasible for patients with muscle invasive bladder cancer (MIBC) in the Australian setting, according to a study published online June 30 in the Journal of Medical Imaging and Radiation Oncology.

Noting that the use of concurrent CON with showed significant improvement in overall survival and local relapse in a U.K. trial, Anzela Anzela, M.B.B.S., from Gosford Hospital in Australia, and colleagues examined the feasibility of setting up a CON radiation oncology department in Australia. The study recruited seven patients with histological locally advanced bladder cancer.

Establishing a CON department took about 24 months. The availability of equipment in Australia supported development of the trial protocol; local occupational, health, and guided proper transport, storage, and handling of the equipment. The researchers note that a full dose of CON was received by all patients. The most commonly reported acute bladder and bowel toxicities were increased urinary frequency, urgency, and diarrhea.

"The practicality in setting-up a CON department and its will provide a new therapeutic option in Australia in the treatment of patients with MIBC," the authors write. "We advocate for wider use of CON in Australia and for this treatment to be part of standard of care in an often-undertreated patient cohort in Australia."


Explore further

Combined modality treatment could be first course for muscle-invasive bladder cancer

More information: Abstract/Full Text (subscription or payment may be required)

Copyright © 2021 HealthDay. All rights reserved.

Citation: Carbogen and nicotinamide with radiation feasible for bladder cancer (2021, July 8) retrieved 28 September 2021 from https://medicalxpress.com/news/2021-07-carbogen-nicotinamide-feasible-bladder-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors